Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) have earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $4.50 for the company, according to Zacks. Zacks has also given ContraVir Pharmaceuticals an industry rank of 179 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $4.00 target price on ContraVir Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 30th.
An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. grew its stake in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after purchasing an additional 366,192 shares during the period. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent SEC filing. Institutional investors own 6.65% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ContraVir Pharmaceuticals Inc (CTRV) Given Consensus Recommendation of “Strong Buy” by Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/22/contravir-pharmaceuticals-inc-ctrv-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.